| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.3 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.3 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.055 | 0.3 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |